Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Randomized, Multicenter Phase II Trial Comparing the Depletion of Malignant Stem Cells With Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Next Previous
Trial Profile

An Open-Label, Randomized, Multicenter Phase II Trial Comparing the Depletion of Malignant Stem Cells With Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dasatinib (Primary) ; Imatinib
  • Indications Chronic myeloid leukaemia
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use

Most Recent Events

  • 04 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record record.
  • 10 Dec 2013 Clinical results presented at the 56th Annual Meeting and Exposition of the American Society of Hematology.
  • 14 Jun 2013 Results presented at the 18th Congress of the European Haematology Association.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top